Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Rifampicin on Methotrexate PK in Elderly
NCT06108453Phase 1Unknown
- Sponsor
- Seoul National University Bundang Hospital
- Start
- Aug 2023
- Primary completion
- Oct 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of methotrexate in rheumatoid arthritis (RA) (2 arms), sponsored by Seoul National University Bundang Hospital. Primary endpoints: Maximum Plasma Concentration of Methotrexate at 24 hours, Area Under the Curve to the Last Measurable Concentration of Methotrexate at 24 hours and 1 more. Status: unknown.
02
Drugs
methotrexate
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT06108453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06108453.